ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 255 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,601 | -24.6% | 990 | 0.0% | 0.02% | -20.0% |
| Q2 2023 | $35,303 | +40.4% | 990 | 0.0% | 0.03% | +15.4% |
| Q1 2023 | $25,146 | -37.4% | 990 | 0.0% | 0.03% | -27.8% |
| Q4 2022 | $40,154 | +21.7% | 990 | 0.0% | 0.04% | +16.1% |
| Q3 2022 | $33,000 | -5.7% | 990 | 0.0% | 0.03% | +3.3% |
| Q2 2022 | $35,000 | -23.9% | 990 | 0.0% | 0.03% | -6.2% |
| Q1 2022 | $46,000 | -30.3% | 990 | 0.0% | 0.03% | -20.0% |
| Q4 2021 | $66,000 | +32.0% | 990 | +23.8% | 0.04% | +25.0% |
| Q3 2021 | $50,000 | -24.2% | 800 | 0.0% | 0.03% | -25.6% |
| Q2 2021 | $66,000 | +24.5% | 800 | 0.0% | 0.04% | +16.2% |
| Q1 2021 | $53,000 | -13.1% | 800 | 0.0% | 0.04% | -19.6% |
| Q4 2020 | $61,000 | +177.3% | 800 | +60.0% | 0.05% | +142.1% |
| Q3 2020 | $22,000 | +46.7% | 500 | +42.9% | 0.02% | +26.7% |
| Q2 2020 | $15,000 | – | 350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |